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Rhabdomyolysis (RM) is a syndrome characterised by
muscle breakdown and necrosis, resulting in elevated
serum concentration of creatine kinase (CK) and myoglo-
binuria [1]. RM ranges from an illness without symptoms
to a life-threatening condition. The classic triad of symp-
toms includes weakness, tea-coloured urine and muscle
pain. RM may involve specific groups of muscles or may
be generalised [2]. The main complication of RM is acute
renal failure (ARF), which develops in 10–50% of RM
cases with a mortality of approximately 20% [1, 2].
The major causes of RM are related to muscular trau-
ma, toxin abuse, drugs, muscle enzyme deficiencies, elec-
trolyte abnormalities, metabolic disorders and seizures.
Infections are generally considered to account for less than
5% of the cases, with just one study reporting an infectious
aetiology in 31% of their RM cases [1, 3]. Legionella,
Streptococcus and Salmonella species are the most com-
mon bacteria which may have a causative role in precipi-
tating RM. Other infectious agents that have been associ-
ated with RM are: influenza virus, HIV, enterovirus and
malaria [2–4]. In infection-associated RM, ARF and mor-
tality reach 57% and 38% respectively [4].
No data is available on Streptococcus pneumoniae-
associated RM before 1982. Between 1982 and 2003 a
total of 20 cases of RM associated with S. pneumoniae
infection were described in the literature [5–8]. In most
cases major underlying conditions were identified: alcohol
abuse and smoking were the most frequent conditions,
while splenectomy was present in three cases [6, 9, 10].
Although S. pneumoniae has been associated with RM, its
appearance generally occurs at the onset of the illness, and
to our knowledge, there are no reports of delayed RM
occurring during a severe pneumococcal infection.
We report a case of a 62-year-old female Italian patient
splenectomised 30 years earlier because of severe thrombo-
cytopenia. She had not been immunised against S. pneumo-
niae, Haemophilus influenzae or Neisseria meningitidis. No
other known underlying conditions for RM were present. The
patient had had fever and myalgia for 4 days, and eventually,
mental confusion and vomiting the day she was admitted to
our hospital. At the emergency unit she experienced a gener-
alised tonic-clonic seizure that immediately resolved with a
single 10-mg dose of diazepam IV bolus. Physical examina-
tion revealed clinical signs of meningitis and her initial
Glasgow Coma Score was 11. Temperature was 38°C, sys-
tolic blood pressure was 120 mmHg, pulse rate was 65 and
respiratory rate was 15. Lumbar puncture performed on
admission showed a slightly cloudy cerebrospinal fluid,
lightly xanthochromic after centrifugation, with 28/mm3
leukocytes, protein >300 mg/dl, glucose 10 mg/dl. Gram
stain showed gram-positive diplococci, and culture yielded a
penicillin-susceptible S. pneumoniae. Arterial blood gas
determination showed a pH of 7.51, pCO2 of 38.1 mmHg,
pO2 of 69.3 mmHg and lactic acid 1.5 mmol/l. Laboratory
results disclosed the following significant data: peripheral
white cell count 27 160 (22980 neutrophils), haematocrit
36.5%, platelets 131 000, AST 37 U/l, ALT 40 U/l, ALP 159
U/l, CK 53 U/l, LDH 294 U/l, myoglobin 58 ng/ml (normal
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values: 0–75 ng/ml), creatinine 1.8 mg/l, serum sodium 146
mEq/l, potassium 3.1 mEq/l, calcium 11.6 mg/dl, ESR 99
mm/h, C-reactive protein 42 mg/dl and fibrinogen 1001
mg/dl. Urine test results were normal and no red cells were
present at the microscopic exam. Urinary antigen was posi-
tive for S. pneumoniae while blood cultures were negative.
The patient received a treatment regimen which included
antibiotic therapy with ceftriaxone (2 g infusion IV bid for 3
weeks), dexamethasone (8 mg bolus IV tid, for 4 days) and
infusions of normal saline solutions and lactated Ringer’s
solutions. Another lumbar puncture was performed as fever,
reduced level of consciousness and mental confusion were
still present after 5 days of therapy. The test results were as
follows: white blood cells (WBC) count 150/mm3, protein
119 mg/dl, glucose 910 mg/dl; stain and culture were nega-
tive. Ten days after the admission, the patient became afebrile
and recovered from the mental disturbances. During this first
period of hospitalisation CK levels remained in the normal
range (20–160 U/l) and the peripheral WBC count dropped to
18 000/mm3. A potassium depletion was observed (lowest
value reached 2.9 mEq/l) and it was corrected to the normal
range with infusions of potassium chloride solution (a total of
240 mEq was given). Two days later the patient reported
muscular weakness and myalgias involving upper and lower
limb muscles. New laboratory studies revealed AST 42 U/l,
ALT 45 U/l, CK 710 U/l, LDH 459 U/l and myoglobin 1614
ng/ml (CK-MB, troponin I and electrocardiography were
normal). The patient’s calcium and magnesium levels
remained within the normal range. Serum sodium and potas-
sium levels were 152 mEq/l and 2.8 mEq/l, respectively,
despite continuous infusion of electrolyte solution and potas-
sium replacement therapy. In the following three days, CK
and myoglobin levels peaked at 8863 U/l and 6257 ng/ml,
respectively, without elevation of the cardiac enzymes.
Arterial blood gas determination showed a pH of 7.59, pCO2
of 31.8 mmHg, pO2 of 65 mmHg and lactic acid 2.3 mmol/l.
A physical exam showed upper and lower limb weakness
with depressed tendon reflexes. Electromyography was per-
formed showing a middle entity sensory and motor polyneu-
ropathy at the lower limbs, which was compatible with criti-
cal illness polyneuropathy. The patient’s renal function was
preserved thanks to aggressive fluid replacement therapy
with normal saline (2500 ml), 1.4% isotonic sodium bicar-
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bonate (500 ml/qd) and 5% glucose solutions (2000 ml/qd)
plus 80 mEq potassium chloride/qd associated with loop
diuretics (furosemide 20 mg IV bolus tid). After four days,
CK and myoglobin levels decreased to the normal range. The
patient was discharged within a week in a stable condition
and with normal blood values.
RM is a potentially life-threatening condition, due to its
complications, which include ARF, cardiac arrhythmias,
disseminated intravascular coagulation, electrolyte imbal-
ance and shock. RM associated with pneumococcal infec-
tion seems to be a clinical indicator of increased morbidity
and mortality [11]. The extent of complications and sur-
vival during the acute stage of RM are dependent on early
diagnosis and insuring therapy is both adequate and timely.
Forced diuresis may protect the kidney function from aci-
dosis and tubular damage. The prognosis for muscular atro-
phy and ARF following the acute stage of RM is excellent
[2, 12, 13]. The role of S. pneumoniae infection as a pre-
cipitating factor of RM is rare and probably under-reported
because patients with pneumococcal infections are seldom
hospitalised. Furthermore, RM is often asymptomatic. The
pathogenesis of skeletal muscle injury resulting from pneu-
mococcal infection is not completely clear [10, 14].
The reported case is characterised by a late onset of RM
(12 days after admission to our hospital) linked to a severe
pneumococcal infection in a patient who had undergone
splenectomy, an underlying condition which predisposes to
RM. In previously reported S. pneumoniae-associated RM,
the onset of muscular damage was already present at the time
of admission to the hospital or it was detected within the first
days of hospitalisation. The peculiarity of this case is the late
onset of the RM. Therefore, we cannot consider the direct
muscle invasion by S. pneumoniae as the primary cause of
the damage. Other possible mechanisms may have played an
important role in the occurrence of this case of RM, such as
toxin production or metabolic effects in reducing the gly-
colytic enzyme activity [15, 16]. However, we must take into
consideration other possible factors that generally contribute
to the genesis of RM. First, we can reasonably exclude drug
toxicity, because no drugs other than those described were
used and none of these drugs are linked to RM. Hypotension
or hyperthermia can be excluded as well, because signs and
symptoms of RM occurred when the patient was haemody-
namically stable and had been afebrile for 11 days. Acidosis
was never detected despite several arterial blood gas analy-
ses. Probably the length of immobilisation and, perhaps of
greater relevance, the persistence of electrolyte abnormali-
ties, although promptly corrected, were significant co-factors
in determining the muscle damage. However, these findings
are very common in the majority of critically ill patients,
even in the absence of RM. We would like to point out that
a Medline search on RM and Pseudomonas aeruginosa or
Acinetobacter gave no results, even though these gram-neg-
ative bacteria are associated with sepsis and are frequently
found in critically ill patients.
Fig. 1 Key points
• RM is a possible severe complication during systemic
infectious diseases
• Streptococcus pneumoniae may be a precipitating
bacteria
• RM may appear as an early or late complication
• Monitor patients with severe Streptococcus pneumoniae
infections for the symptoms of RM and check CK levels
several times during the course of their illness
Another important point to remember is the need to
administer the pneumococcal vaccine to patients at high
risk for a potentially lethal S. pneumoniae infection like
our splenectomised patient.
In conclusion, we cannot consider the S. pneumoniae
infection as the sole and unique cause of the RM case here
reported. Its occurrence leads us to emphasise the impor-
tance of monitoring the CK levels in patients with pneu-
mococcal infections even when the critical phase of the
infection has resolved. Following the CK level would
allow prompt detection and treatment of RM.
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The review of Marietta et al. [1] and the accompanying com-
mentary of Edlow [2] emphasised well the favourable results,
obtained in the frame of a phase 2 trial, of recombinant acti-
vated factor VII (rFVIIa) in the treatment of intracerebral
haemorrhage [3]. The original study of Mayer et al. [3], to
which they refer, was indeed a significant breakthrough in the
management of a dramatic clinical condition with a paucity
of effective therapeutic weapons. However, even in the orig-
inal study, an excess of thrombotic complications emerged as
a significant problem [3]. In the rFVIIa-treated group 7% of
patients had myocardial infarction or ischaemic stroke, com-
pared with a rate of 2% in those receiving placebo. The situ-
ation concerning thrombotic complications is likely to be
even more gloomy than it appears from the published report
[3], because during the trial an important exclusion criterion
was modified. Originally, excluded patients were only those
who had thromboembolic events within 30 days before start-
ing the study, but subsequently exclusion was extended to all
patients with any history of thromboembolism [3]. It can be
easily understood how this midway change of exclusion cri-
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